CareDx Inc
NASDAQ:CDNA

Watchlist Manager
CareDx Inc Logo
CareDx Inc
NASDAQ:CDNA
Watchlist
Price: 23.13 USD 2.44% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
CareDx Inc?
Write Note

CareDx Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CareDx Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
CareDx Inc
NASDAQ:CDNA
Stock-Based Compensation
$50.2m
CAGR 3-Years
16%
CAGR 5-Years
21%
CAGR 10-Years
61%
Abbvie Inc
NYSE:ABBV
Stock-Based Compensation
$872m
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
14%
Gilead Sciences Inc
NASDAQ:GILD
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Stock-Based Compensation
$739.3m
CAGR 3-Years
21%
CAGR 5-Years
16%
CAGR 10-Years
17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CareDx Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in South San Francisco, California and currently employs 633 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The firm offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its suite of AlloSeq products include AlloSeq Tx, AlloSeq cfDNA, AlloSeq HCT, TruSight HLA, Olerup SSP and QTYPE. The company develops and provides diagnostic surveillance testing services for various transplant recipients.

CDNA Intrinsic Value
16.9 USD
Overvaluation 27%
Intrinsic Value
Price

See Also

What is CareDx Inc's Stock-Based Compensation?
Stock-Based Compensation
50.2m USD

Based on the financial report for Sep 30, 2024, CareDx Inc's Stock-Based Compensation amounts to 50.2m USD.

What is CareDx Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
61%

Over the last year, the Stock-Based Compensation growth was -2%. The average annual Stock-Based Compensation growth rates for CareDx Inc have been 16% over the past three years , 21% over the past five years , and 61% over the past ten years .

Back to Top